Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.06 USD
-0.43 (-7.83%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $5.08 +0.02 (0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Editas Medicine, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 323 | 344 | 500 | 402 | 457 |
Receivables | 10 | 5 | 0 | 6 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 7 | 7 | 11 | 6 |
Total Current Assets | 341 | 357 | 507 | 419 | 464 |
Net Property & Equipment | 12 | 16 | 17 | 14 | 11 |
Investments & Advances | 104 | 93 | 120 | 110 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 9 | 5 | 7 | 5 | 5 |
Total Assets | 499 | 514 | 677 | 573 | 509 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 10 | 5 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 35 | 31 | 20 | 24 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 8 | 11 | 21 | 26 |
Total Current Liabilities | 63 | 60 | 47 | 58 | 60 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 61 | 61 | 61 | 74 | 163 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 0 | 0 | 28 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 150 | 154 | 124 | 179 | 246 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,580 | 1,442 | 1,412 | 1,059 | 812 |
Retained Earnings | -1,231 | -1,078 | -858 | -665 | -549 |
Other Equity | 0 | -4 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 349 | 361 | 554 | 394 | 262 |
Total Liabilities & Shareholder's Equity | 499 | 514 | 677 | 573 | 509 |
Total Common Equity | 349 | 361 | 554 | 394 | 262 |
Shares Outstanding | 81.60 | 68.70 | 68.40 | 62.60 | 51.30 |
Book Value Per Share | 4.28 | 5.25 | 8.09 | 6.29 | 5.12 |
Fiscal Year End for Editas Medicine, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 296 | 323 | 350 | 432 | 318 |
Receivables | 0 | 10 | 2 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 8 | 7 | 7 | 6 |
Total Current Assets | 306 | 341 | 359 | 441 | 324 |
Net Property & Equipment | 13 | 12 | 12 | 13 | 13 |
Investments & Advances | 81 | 104 | 97 | 48 | 83 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 9 | 9 | 6 | 5 | 7 |
Total Assets | 440 | 499 | 505 | 542 | 464 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 8 | 10 | 8 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 31 | 35 | 30 | 28 | 32 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 8 | 8 | 8 | 8 |
Total Current Liabilities | 66 | 63 | 59 | 55 | 57 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 54 | 61 | 61 | 61 | 61 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 146 | 150 | 144 | 142 | 147 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,588 | 1,580 | 1,574 | 1,570 | 1,447 |
Retained Earnings | -1,293 | -1,231 | -1,212 | -1,167 | -1,127 |
Other Equity | 0 | 0 | -1 | -2 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 294 | 349 | 360 | 400 | 317 |
Total Liabilities & Shareholder's Equity | 440 | 499 | 505 | 542 | 464 |
Total Common Equity | 294 | 349 | 360 | 400 | 317 |
Shares Outstanding | 82.20 | 81.60 | 81.60 | 81.60 | 69.00 |
Book Value Per Share | 3.58 | 4.28 | 4.42 | 4.90 | 4.60 |